Neuroprotective Effect of Diplocyclos palmatus on Aβ (25-35) Induced Alzheimer's Disease in Mice

被引:0
|
作者
Manda, Rama [1 ]
Yellu, Narsimha Reddy [1 ]
机构
[1] Kakatiya Univ, Univ Coll Pharmaceut Sci, Dept Pharmacol, Warangal 506009, Telangana, India
关键词
Alzheimer's disease; Diplocyclos palmatus; Acetylcholinesterase; MEMORY IMPAIRMENT; EXTRACT; ACETYLCHOLINESTERASE; FRACTIONS; PROTEIN; MODEL;
D O I
10.5530/jyp.2024.16.62
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Alzheimer's disease is primarily caused by neurotoxic effects of amyloid beta A(3(25-35) peptide accumulation and increased levels of Acetylcholinesterase Enzyme (AChE). Acetylcholinesterase inhibitors report for the effective management of cognitive and motor disorders. In the current study the impact of Diplocyclos palmatus Methanolic (DPM) seed extract and its Chloroform (DPC) fractions were investigated in mice with Amyloid beta (A(3)-induced experimental Alzheimer's disease. Materials and Methods: Acute toxicity study was performed based on the guidelines of OECD 423 and doses were selected. Mice were administered with standard Donepezil (5 mg/kg/oral) and two doses each of DPM and DPC daily for 21 days (200 mg/kg and 400 mg/kg/oral). A(3 was given by Intra Cerebro Ventricular (ICV) injection in a single dose 3 mg/kg. Cognitive abilities were assessed using the conditioned avoidance test, the rectangular maze and Y-maze. On 22nd day mice were sacrificed, then isolated brain homogenate used for estimation of biochemical parameters such as reduced Glutathione peroxidase (reduced DPC extracts effectively reduces behavioral and biochemical abnormalities in dose dependent way. Conclusion: Diplocyclos palmatus seeds showed neuroprotective effect on A(3-induced AD in mice due to their antioxidant and AChE activity.
引用
收藏
页码:480 / 487
页数:8
相关论文
共 50 条
  • [41] Interaction of the Alzheimer Aβ(25-35) peptide segment with model membranes
    Cuco, Andreia
    Serro, Ana Paula
    Farinha, Jose Paulo
    Saramago, Benilde
    da Silva, Amelia Goncalves
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2016, 141 : 10 - 18
  • [42] Neuroprotective Effect of Caffeine in Alzheimer's Disease
    Yelanchezian, Y. Mukish
    Waldvogel, Henry J.
    Faull, Richard L. M.
    Kwakowsky, Andrea
    MOLECULES, 2022, 27 (12):
  • [43] Induced β-Barrel Formation of the Alzheimer's Aβ25-35 Oligomers on Carbon Nanotube Surfaces: Implication for Amyloid Fibril Inhibition
    Fu, Zhaoming
    Luo, Yin
    Derreumaux, Philippe
    Wei, Guanghong
    BIOPHYSICAL JOURNAL, 2009, 97 (06) : 1795 - 1803
  • [44] Autoimmune responses to amyloid structures of Aβ(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease
    Grudena, MA
    Davudova, TB
    Malisauskas, M
    Zamotin, VV
    Sewell, RDE
    Voskresenskaya, NI
    Kostanyan, IA
    Shrestnev, VV
    Morozova-Roche, LA
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 18 (02) : 165 - 171
  • [45] Amyloid-induced aggregation and precipitation of soluble proteins:: A electrostatic contribution of the Alzheimer's β(25-35) amyloid fibril
    Konno, T
    BIOCHEMISTRY, 2001, 40 (07) : 2148 - 2154
  • [46] Role of amyloid beta (25-35) neurotoxicity in the ferroptosis and necroptosis as modalities of regulated cell death in Alzheimer's disease
    Naderi, Soudabeh
    Khodagholi, Fariba
    Pourbadie, Hamid Gholami
    Naderi, Nima
    Rafiei, Shahrbanoo
    Janahmadi, Mahyar
    Sayehmiri, Fatemeh
    Motamedi, Fereshteh
    NEUROTOXICOLOGY, 2023, 94 : 71 - 86
  • [47] Human platelet calcium mobilisation in response to β-amyloid (25-35):: buffer dependency and unchanged response in Alzheimer's disease
    Hedin, HLM
    Eriksson, S
    Fowler, CJ
    NEUROCHEMISTRY INTERNATIONAL, 2001, 38 (02) : 145 - 151
  • [48] Subcellular and metabolic examination of amyloid-β peptides in Alzheimer disease pathogenesis: Evidence for Aβ25-35
    Kaminsky, Yury G.
    Marlatt, Michael W.
    Smith, Mark A.
    Kosenko, Elena A.
    EXPERIMENTAL NEUROLOGY, 2010, 221 (01) : 26 - 37
  • [49] Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25-35 model of Alzheimer's disease
    Galoyan, Armen A.
    Sarkissian, John S.
    Chavushyan, Vergineh A.
    Meliksetyan, Irina B.
    Avagyan, Zaruhi E.
    Poghosyan, Mikhail V.
    Vahradyan, Hasmik G.
    Mkrtchian, Hovhannes H.
    Abrahamyan, Davit O.
    ALZHEIMERS & DEMENTIA, 2008, 4 (05) : 332 - 344
  • [50] Coinjection of amyloid β peptide(25-35) and ibotenic acid does not create an animal model for Alzheimer's disease.
    Laksafoss, T
    Jorgensen, OS
    EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 : 93 - 93